This study investigates the correlation between oxaliplatin-induced toxicity and blood levels of HMGB1 in patients with oesogastric and pancreatic adenocarcinoma. It focuses on understanding the potential role of HMGB1 in the development of sinusoidal obstruction syndrome (SOS) and chemotherapy-induced peripheral neuropathy (CIPN) after oxaliplatin treatment.

The study evaluates the biological processes that may link oxaliplatin treatment to SOS and CIPN, with a particular focus on HMGB1 as a possible mediator. It explores whether increased levels of HMGB1 are associated with these toxicities, potentially paving the way for personalized treatment strategies targeting this pathway.

• Who can participate: Adults with a histological diagnosis of oesogastric or pancreatic adenocarcinoma who have resectable tumors and are able to undergo laparoscopy may participate. Participants must also have an ECOG WHO Performance status of 0 or 1 and be able to speak and understand French.
• Study details: Participants will undergo routine management, including an initial laparoscopy and post-oxaliplatin surgical excision. The study will involve monitoring blood levels of HMGB1 to assess its potential role in oxaliplatin-induced toxicities.